Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2008-07-02
2010-11-30
Hartley, Michael G (Department: 1618)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
active
07842806
ABSTRACT:
The disclosure relates to pyrido[2,3-d]pyrimidone compounds, to the preparation thereof and to the therapeutic use thereof, wherein said compounds are of general formula (I):in the form of a base or of an addition salt with an acid which is pharmaceutically acceptable, in the form of hydrates or of solvates, and also in the form of enantiomers, diastereoisomers and a mixture thereof. The disclosure also relates to processes for preparing said compounds, to pharmaceutical compositions containing a compound of general formula (I), and to the therapeutic use of said compounds and compositions.
REFERENCES:
patent: 3534039 (1970-10-01), Davoll
patent: 5620981 (1997-04-01), Blankley et al.
patent: 5733913 (1998-03-01), Blankley et al.
patent: 5733914 (1998-03-01), Blankley et al.
patent: 5952342 (1999-09-01), Blankley et al.
patent: 2007/0167469 (2007-07-01), Bourrie
patent: 0 790 997 (2000-03-01), None
patent: WO 96/15128 (1996-05-01), None
patent: WO 96/34867 (1996-11-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/55147 (2001-08-01), None
patent: WO 01/70741 (2001-09-01), None
patent: WO 02/12238 (2002-02-01), None
patent: WO 03/000011 (2003-01-01), None
patent: WO 2004/063195 (2004-07-01), None
patent: WO 2004/085436 (2004-10-01), None
patent: WO 2005/105097 (2005-11-01), None
patent: WO 2006/007693 (2006-01-01), None
patent: WO 2006/016067 (2006-02-01), None
patent: WO 2007/003765 (2007-01-01), None
U.S. Appl. No. 11/955,583, filed Dec. 13, 2007, Bourrie.
Alam, Fighting Cancer: ‘Magic Bullets’ on Target to Lead Market, Pharmalicensing.com (Mar. 8, 2005).
Anzali et al, 1. Endothelin antagonists: Search for Surrogates of Methylendioxyphenyl by Means of a Kohonen Neural Network, Bioorganic & Medicinal Chemistry Letters 8 (1998) pp. 11-16.
Lewell et al, Drug Rings Database with Web Interface. A Tool for Identifying Alternative Chemical Rings in Lead Discovery Programs, J. Med. Che. 2003, 46, pp. 3257-3274.
Mederski et al, 2. Endothelin Antagonists: Evaluation of 2,1,3-Benzothiadiazole as a Methylendioxyphenyl Bioisoster, Bioorganic & Medicinal Chemistry Letters 8 (1998) pp. 17-22.
Palmer et al, Structure-activity Relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as Inhibitors of the Cellular Checkpoint Kinase Wee1, Bioorganic & Medicinal Chemistry Letters 15 (2005) pp. 1931-1935.
Schroeder et al, Soluble 2-Substituted Aminopyrido[2,3-d]primidin-7-yl Ureas. Structure—Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity, J. Med. Chem., 2001, 44, 1915-1926.
Sicinski, Killer Breast Cancer Therapy Hope, BBC News/Health Jan. 21, 2006.
Thompson et al, Synthesis and Structure—Activity Relationships of Soluble 7-Substituted 3-(3,5-DimethoxyphenyI)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receiptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases, J. Med. Chem., 2005,48, 4628-4653.
Walsh, No ‘Magic Bullet’ Cure for Cancer, BBC News, International Version, Medical Notes, Feb. 1, 2007.
Albrecht, Untersuchungen uber die antibakterielle Aktivitat von Chinoloncarbonsauren. VI (1). Der Einfluss von kondensierten Funfringen and 1-Substituenten, Eur. J. Med. Chem.-Chimica Therapeutica, 1977 (12) 3 pp. 231-235.
Carmichael et al, Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing, Cancer Research, 1987 (47) pp. 936-942.
Clark et al, Synthesis and Analgesic Activity of 1,3-Dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(Substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines, J. Med. Chem., 1978 (21) 9 pp. 965-978.
Colomb et al, Nuclear Texture Parameters as Discriminant Factors in Cell Cycle and Drug Sensitivity Studies, Cytometry, 1991 (12) pp. 15-25.
Drexler, Leukemia Cell Lines: in vitro Models for the Study of Chronic Myeloid Leukemia, Leukemia Research, 1994 (12) 12 pp. 919-927.
El Hadri et al, New Series of N-substituted Phenyl Ketone Oxime Ethers: Synthesis and Bovine Beta3-adrenergic Agonistic Activities, Pharmazie, 2003 (58) pp. 13-17.
Fujishita, et al, Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel, Oncology, 2003 (64) pp. 399-406.
Klutchko et al, 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity, J. Med. Chem., 1988 (41) pp. 3276-3292.
Koeffler et al, An Undifferentiated Variant Derived From the Human Acute Myelogenous Leukemia Cell Line (KG-1), Blood, 1980 (56) 2 pp. 265-273.
Kuriyama et al, CLM-T1: A Cell Line Derived From T-Lymphocyte Acute Phase of Chronic Myelogenous Leukemia, Blood, 1989 (74) 4 pp. 1381-1387.
Lozzio et al, Brief Communication: Cytotoxicity of a Factor Isolated From Human Spleen, J Natl Cancer hist, 1973 (50) pp. 535-538.
Lozzio et al, Human Chronic Myelogenous Leukemia Cell-line with Positive Philadelphia Chromosome, Blood, 1975 (45) pp. 321-334.
Soda et al, Lymphoid Crisis with T-cell Phenotypes in a Patient with Philadelphia Chromosome Negative Chronic Myeloid Leukaemia, British Journal of Haematology, 1985 (59) pp. 671-679.
Westphal et al, Epidermal Growth Factor Receptors in the Human Glioblastoma Cell Line SF268 Differ From Those in Epidermoid Carcinoma Cell Line A431, Biochemical and Biophysical Research Comm., 1985 (132) 1 pp. 284-289.
Willard et al, Potential Diuretic—Beta-Adrenergic Blocking Agents: Synthesis of 3-[2[(1,1-Dimethylethyl) amino]-1-hydroxyethyl]-1,4-dioxino[2,3-g]quinolines, J. Org. Chem., 1981 (46) 19 pp. 3846-3852.
Bourrie Bernard
Casellas Pierre
Durand Florence
Jegham Samir
Labrosse Jean-Robert
Bender Kelly L.
Gembeh Shirley V
Hartley Michael G
sanofi-aventis
LandOfFree
Pyridopyrimidone derivatives, preparation thereof,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridopyrimidone derivatives, preparation thereof,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridopyrimidone derivatives, preparation thereof,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163520